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Differential clonal evolution in oesophageal cancers
in response to neo-adjuvant chemotherapy
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How chemotherapy affects carcinoma genomes is largely unknown. Here we report
whole-exome and deep sequencing of 30 paired oesophageal adenocarcinomas sampled
before and after neo-adjuvant chemotherapy. Most, but not all, good responders pass through
genetic bottlenecks, a feature associated with higher mutation burden pre-treatment. Some
poor responders pass through bottlenecks, but re-grow by the time of surgical resection,
suggesting a missed therapeutic opportunity. Cancers often show major changes in driver
mutation presence or frequency after treatment, owing to outgrowth persistence or loss of
sub-clones, copy number changes, polyclonality and/or spatial genetic heterogeneity.
Post-therapy mutation spectrum shifts are also common, particularly C4A and TT4CT
changes in good responders or bottleneckers. Post-treatment samples may also acquire
mutations in known cancer driver genes (for example, SF3B1, TAF1 and CCND2) that are
absent from the paired pre-treatment sample. Neo-adjuvant chemotherapy can rapidly and
profoundly affect the oesophageal adenocarcinoma genome. Monitoring molecular changes
during treatment may be clinically useful.
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O
esophageal adenocarcinoma (EAC) is routinely treated
with neo-adjuvant chemotherapy or chemo-radiotherapy
before surgical resection. Clinicopathological response to
this therapy is variable and is currently the primary predictor of
survival and recurrence after surgery, but overall prognosis
remains poor1,2. It is plausible that some tumours are intrinsically
therapy-resistant, while others are partially sensitive or contain a
mixed population of sensitive and resistant cells (Supplementary
Fig. 1). It appears, however, that most cancers contain at least
some resistant cells3.
The differences in therapeutic response among tumours might
reﬂect several factors, including tumour genetics or epigenetics.
Certain (epi)mutations in the pre-treatment sample might confer
almost homogenous resistance or sensitivity to therapy, similar
to that seen for KRAS-mutant cancers treated with targeted
EGFR inhibitors4. Alternatively, resistant tumour sub-clones
might carry (epi)mutations in resistance genes, although these
(epi)mutations may be rare and difﬁcult to detect in the
pre-treatment sample. A longstanding example here is
methylation of MLH1, and the resultant subsequent
microsatellite instability, that can occur in ovarian cancers after
platinum-based chemotherapy5. However, differences in response
are not necessarily determined by genetic or epigenetic changes,
and other factors such as hypoxia6, the cancer stem cell
phenotype7, and stromal microenvironment8,9 have been
implicated in therapeutic resistance.
The ability to perform repeated sampling with minimal patient
risk makes haematological malignancies ideal for studying how
neoplastic genomes change over time. Several such studies have
shown mutations in speciﬁc genes to differ between leukaemia
cells at presentation and relapse (for example, refs 10–12), and
more recently, genome-wide sequencing has greatly increased our
insights into how leukaemias and lymphomas evolve in patients
who relapse following induction of remission with
chemotherapy13–17. These studies have largely shown the
lesions at presentation to be monoclonal or oligoclonal. In
general, the relapses are clearly genetically related to the
presenting clone, but may have reduced complexity and a
number of ‘private’ mutations, consistent with genetic
bottlenecking followed by outgrowth of a clone that has not
been killed by the chemotherapy used. These ﬁndings have led to
speculation as to whether similar genetic phenomena occur
during the treatment of solid adult malignancies, particularly
cancers with low response rates to chemotherapy.
Solid tumours, such as EAC, differ from ‘liquid tumours’ in
their cellular and molecular origins, their environments, their
clonal structures and dynamics, and their rates of response to
non-surgical therapy. Multi-region sampling of primary cancers
and metastases has shown varying degrees of branched tumour
evolution, including the divergence of metastases from primary
cancers at very early stages, parallel or convergent evolution (in
which the same driver genes acquire different mutations in
different regions of the tumour), and widely varying mutation
rates, spectra and signatures (for example, refs 18–20). Where
molecularly targeted therapies have been used, sequential biopsies
of solid tumours and/or serial samples of circulating tumour cells
or DNA have conﬁrmed that most of the cells carrying the
targeted mutation can be killed, but resistance usually develops
owing to pre-existing reversion mutations in the targeted protein
or a different component of its pathway (for example, refs 21–27).
In studies of chemotherapeutic regimens, small gene sets or
panels have shown that the frequencies of speciﬁc mutations or
molecular phenotypes can change signiﬁcantly28–31. Recently,
studies of gliomas and glioblastomas have begun to examine how
the exomes and genomes of solid tumours change following
radiotherapy and chemotherapy, with some tumours showing
major clonal shifts32,33. However, brain tumour evolution may be
quite different from that of the common cancers, and little is
known about how carcinoma genomes alter in response to
genotoxic therapy34,35. Moreover, the use of neo-adjuvant
chemotherapy to shrink tumours such as EAC before surgery
provides the opportunity to compare the evolution of cancers
that respond well and poorly, since response is rarely
clinicopathologically complete and the majority of patients still
undergo surgery.
In this study, we investigated the effects of therapy on EACs,
comparing primary tumours with paired samples after two cycles
of neo-adjuvant 5-ﬂuorouracil and oxaliplatin. Our main aim was
to examine how chemotherapy affected the architecture of
the oesophageal cancer genome in responders compared with
non-responders. A subsidiary aim was to identify mutations
driving therapeutic resistance or tumour growth in responders
after treatment.
Results
Overview of patients and sequencing strategy. Oesophageal
cancer patients in the study (Table 1; Supplementary Table 1)
received two cycles of oxaliplatin-5FU, each lasting 21
days (Methods). Following completion of therapy, restaging was
performed by positron emission tomography-computed
tomography (PET-CT). In the absence of progression to
metastatic and/or unresectable disease, patients underwent
attempted surgical resection 4–6 weeks later. Thirty EAC patients
were enrolled for molecular analysis, representing 15 cases who
had a clinically signiﬁcant, but incomplete, pathological response
to neo-adjuvant therapy (Mandard grade 2 or 3, ‘responders’) and
Table 1 | Clinical features of each patient.
Case no. Age Sex T N PathR Mandard
1 69 Male 2 0 Yes 3
2 78 Male 3 1 Yes 3
3 49 Male 3 1 Yes 3
4 53 Male 2 1 Yes 3
5 73 Male 3 0 Yes 2
6 63 Male 2 0 Yes 2
7 68 Male 3 1 Yes 3
8 54 Male 3 0 Yes 2
9 58 Female 2 0 Yes 3
10 61 Male 1 1 Yes 3
11 71 Male 3 1 No 4
12 56 Female 3 1 No 5
13 67 Male 2 1 No 4
14 62 Male 3 1 No 4
15 67 Male 2 1 No 4
16 60 Male 3 1 No 4
17 77 Male 3 1 No 5
18 68 Female 2 0 No 5
19 65 Male 2 3 No 4
20 65 Male 3 1 Yes 3
21 70 Male 3 1 No 4
22 60 Male 3 0 Yes 3
23 73 Male 3 0 Yes 3
24 57 Male 1 1 No 5
25 65 Female 3 1 No 4
26 76 Male 2 0 No 4
27 78 Female 4 0 Yes 3
28 74 Male 2 0 Yes 3
29 29 Male 3 0 No 5
30 69 Female 3 1 No 4
T, N AJCC tumour and node stage; PathR, binary pathological response derived from Mandard
score, Mandard, Mandard response grade. Further details are provided in Supplementary Table 1.
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15 with very limited or no response (Mandard grade Z4,
‘non-responders’)1,2,36. Each patient provided two fresh-frozen
(FF) cancer samples, one ‘pre-treatment’ at endoscopic biopsy
and one ‘post-treatment’ at surgical resection. Matched,
histologically normal oesophageal tissue distinct from the
cancer was also obtained before treatment. Additional paired or
unpaired formalin-ﬁxed, parafﬁn-embedded (FFPE) cancer
samples were available from a sub-set of 20 patients.
After histological review (Supplementary Fig. 2), the FF sample
trios from each patient underwent exome capture and sequencing
to median depth of 74 (range 36–133 , Supplementary
Fig. 3). The median somatic single nucleotide variant (SNV) and
small insertion/deletion (indel) burden in the exome and other
captured regions was 373 (range 50-6023) in pre-treatment
samples, and this reduced to 272 (range 51–7051) in post-
treatment samples (Po0.001, Wilcoxon test). Two cancers were
microsatellite-unstable (microsatellite instability (MSI)þ ) in
both pre-and post-treatment samples and these had very elevated
SNV and indel burdens. Further sequencing metrics are shown in
Supplementary Fig. 3.
We additionally performed deep sequencing of all available FF
samples using the Ampliseq Comprehensive Cancer Panel, which
contained most of the putative EAC drivers and a total of 409
genes. Median average read depths of 1,888 and 1,787 were
achieved in the pre- and post-treatment cancers. The matched
normal pre-treatment samples were sequenced at standard depth
(median¼ 224 ). Of 278 SNVs and small indels found by
exome sequencing within Comprehensive Cancer Panel genes,
97% were conﬁrmed by Ampliseq, with very strong concordance
between variant allele frequencies (VAFs) from the two platforms
despite the different sequencing depths (Supplementary Fig. 4).
The pre-treatment EAC genome. Exome sequencing showed
that nearly all (28/30, 93%) cancers carried potentially functional
(non-synonymous, protein-truncating or splice site) somatic
SNVs in one or more of the previously postulated EAC driver
genes (Fig. 1; Supplementary Table 2)37,38. TP53 (p53) was
mutated in 23 (77%) of the pre-treatment cancers and all of
these changes were protein-truncating or missense mutations
previously shown to be pathogenic. Other frequently mutated
EAC driver genes included NOTCH1 (N¼ 8 cancers), ARID1A
(N¼ 7), CNTNAP5 (N¼ 3), PIK3CA (N¼ 3) and SMARCA4
(N¼ 3) (Supplementary Tables 2 and 3). Additional genes with
well-established roles in tumorigenesis (for example, CDKN2A,
FBXW7 and SMAD4) also harboured SNVs and indels of
previously proven pathogenic effect. Of interest, the MSIþ
cancers tended to harbour pathogenic mutations in classical
colorectal cancer driver genes such as KRAS, ACVR2A, PTEN,
BAX and CTNNB1. We found two cancers with mutations
(p.Arg298Cys and p.Arg259X) in STAG2, a gene not previously
associated with EAC, but known to be a driver gene in other
cancer types39; further exploration of TCGA EAC exome data
found 6 of 88 tumours with STAG2 mutations (https://
tcga-data.nci.nih.gov/tcga/). Intogen40 and MutSigCV41 analysis
did not identify any further EAC driver genes at false discovery
rate o0.05 and no pathogenic mutations were found in some of
the previously suggested EAC drivers38,42, including TRIM58,
PNLIPRP3, UNC13B, TLR4 and CCDC102B (ref. 39).
Excluding a small number of mutations in regions of poor
coverage in the Ampliseq panel, the high-depth sequencing on
the same FF samples validated 66/70 (94%) of the driver SNVs
and small indels. In addition, 10 mutations in EAC driver genes
were called only in the Ampliseq data, including probably
pathogenic changes in p53, SMAD4, CDKN2A, PIK3CA and
NOTCH1 (Supplementary Tables 3 and 4). The reasons for these
changes not being present in the exome data were various,
including low depth of coverage, low regional sequencing quality,
and VAF below the calling threshold. In all cases where coverage
and quality were acceptable, the mutation was retrospectively
found to be present in the exome sequencing data. No driver was
universally predicted to be clonal or sub-clonal, p53 and
SMARCA4 tending to be in the former category and NOTCH1
in the latter.
SNV mutation spectra and signatures for all samples are shown
in Fig. 2 and Supplementary Fig. 5. Almost all pre-treatment
samples showed a predominant signature S3. This partially
resembled the aging-associated Signature 1 of Alexandrov et al.43,
with a predominance of C4T changes at CpG dinucleotides, but
also included .TT4.GT changes, as previously noted in
treatment-naive EACs37,44. In agreement with these data,
patient age was positively correlated with the proportion of
C4T changes in the pre-treatment samples (P¼ 0.038). The
.TT4.GT mutations were not related to age (P¼ 0.762), perhaps
because they originated from inﬂammation-induced oxidative
damage in precursor lesions such as Barrett’s oesophagus38. Of
particular note, we found two further signatures (S1, S2) in some
of our cancers: S1 resembled the Alexandrov smoking-associated
signature #4 typiﬁed by C4A changes, whereas S2 did not clearly
map to an Alexandrov signature, being characterized by both
T4C (especially .TT4.CT) and C4A changes. S1 was the
predominant signature in two cancers (#17 and #20) and S2 was
present only in case #29, suggesting that these cancers arose
owing to an aetiology that was not related to ageing and may have
been acting throughout tumorigenesis. Patient #29, in particular,
was exceptionally young (aged 29 years at presentation). His
cancer had an unusual histology (Supplementary Fig. 2) and a
relatively low mutation burden, and he was found to carry a p53
mutation in his morphologically normal oesophagus. DNA from
other cell types was not available and no family history of cancer
had been reported, suggesting that this patient may have been
somatic mosaic for mutant p53.
In most cancers (N¼ 23), we were able to assess somatic copy
number alterations (SCNAs) and loss of heterozygosity (LOH)
using SNP arrays. EACs were generally hypertriploid, and as
others have noted previously38,45,46, chromosome arm-scale
SCNAs were common (Supplementary Fig. 6), especially gains
of chromosome 5p, 8q and 13q, and deletions of 4q, 9p, 15q, 17p,
19 and 22q. A median 18 large SCNAs, deﬁned for convenience
as changes involving more than half of a chromosome arm, were
found per cancer (Supplementary Fig. 6). Focal SCNAs included
ampliﬁcation of known oncogenes (including ERBB2, TERT,
MYC and CCNE1) and loss of tumour suppressors (including
ARID1A and CDKN2A) (Supplementary Table 5). The two
MSIþ cancers showed very few SCNAs and were hyperdiploid.
Several of the focal SCNAs represented actionable targets for
therapy (Supplementary Table 6). In addition, a number of SNVs
was potentially actionable, although some of these mutations
were of uncertain pathogenic signiﬁcance. The actionable changes
were present variably in pre- and/or post-treatment samples,
and hence not only represented potential targets for second-line
therapy, but also suggested the potential utility of adding targeted
therapy to ﬁrst-line genotoxic treatment.
We searched for clinically useful molecular predictors of
response to chemotherapy in the pre-treatment tumour.
Response to chemotherapy was not associated (at Po0.05)
with any speciﬁc mutated gene or SCNA, or with the burden of
these changes, although there was evidence that a higher burden
of pre-treatment SNVs and indels was associated with a good
response (Supplementary Table 7). Neither MSIþ cancer
responded well, in accord with the reported poor response of
MSIþ colorectal cancers to chemotherapy47. Based on ﬁndings
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linking intra-tumour variability to outcome in other
cancers18,34,48, we also used the VAF coefﬁcient of variation
in pre-treatment samples as a simple measure of genetic
diversity, but this was not associated with response (P¼ 0.178,
Wilcoxon test). The proportion of T:A4A:T mutations in the
pre-treatment sample was, however, associated with response
independent of other clinico-pathological factors (median 7.1%
T4A in responders versus 4.8% in non-responders, P¼ 0.0028,
Wilcoxon test; odds ratio using median¼ 16, Supplementary
Table 7).
All patients had a minimum follow-up of 5 years. In
multivariate models, a good pathological response and absence
of lymph node metastases were associated with better recurrence-
free survival in a Cox proportional hazards model, as expected2,
but no pre-treatment molecular or clinical variable predicted
survival (Supplementary Table 7).
Driver mutation changes following chemotherapy. We initially
observed from the exome data that some cancers, especially
clinical responders, showed large decreases in mutation burden
after treatment (Supplementary Fig. 7; Supplementary Table 3).
Since neo-adjuvant therapy can result in lesions with low tumour
cell content, we assessed this possibility carefully (Supplementary
Note 1). As a result, we excluded six post-treatment samples (four
responders, two non-responders) on the basis of three features
(Fig. 1; Supplementary Note 1): estimated large decreases in
purity between the pre- and post-treatment samples; likely low
tumour cell content (o20% in histological sections); and low
mutation burden after therapy. After this process, several of the
24 remaining cancers still showed complete loss of mutations,
including driver changes such as p53, SMARCA4 and ARID1A,
and complete gain of mutations was also observed, although less
frequently (Fig. 1; Supplementary Table 3; Supplementary Fig. 7).
We then assessed other explanations for these observations,
principally: (i) copy number losses that deleted the mutation;
(ii) intra-tumour heterogeneity/polyclonality, causing apparent
mutation loss through tumour sampling; and (iii) clonal evolu-
tion as a result of therapy. We used p53 as an exemplar for the
behaviour of EAC driver mutations after chemotherapy, owing to
its relatively high mutation frequency and its established role in
tumorigenesis from the stage of severe dysplasia onwards.
First, where assessment using SNP arrays could be performed,
we found evidence that deletions in the post-treatment sample
could contribute to decreased mutation VAF. For example,
reduced chromosome 17p (p53) copy number occurred after
therapy in cancers #5, #8 and #22, all of which showed loss of a
p53 missense or nonsense mutation. Conversely, p53 copy
number increase occurred after treatment in #27, which showed
gain of a p53 missense mutation.
Second, several cancers showed evidence of intra-tumour
heterogeneity/polyclonality, as reﬂected by the presence of
multiple p53 mutations that behaved discordantly after therapy
(Fig. 3; Supplementary Table 3). The MSIþ cancers were in this
group, perhaps as expected, but other cancers (#1, #11) showed
similar features.
Third, in a single case (#6), loss of p53 mutation could be
ascribed with conﬁdence to clonal evolution after therapy (Fig. 4).
This cancer showed no post-treatment copy number change at p53,
evidence of problematic purity, or polyclonality for p53. Similarly,
SMAD4 mutation was lost in cancer #8, and actually showed copy
number gain, strongly suggesting loss of its sub-clone.
Clonal evolution of the EAC genome after chemotherapy. We
then assessed in more detail the evolution of the 24 EACs as a
result of chemotherapy and found a variety of clonal behaviours
(Fig. 4; Supplementary Table 1; Supplementary Fig. 8). Eleven
cases (9 non-responders, 2 responders) showed little change in
clonal composition after therapy (Figs 1 and 3). In these lesions,
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Figure 1 | Summary of mutations and other molecular features in each
cancer from exome sequencing. PathR: pathological response (pink) or
non-response (clear). Evolution: putative bottleneck (pink), polyclonality
(grey), no major clonal change (clear) or excluded owing to concerns about
tumour purity as detailed in Supplementary Note 1 (absent). Mutant genes:
yellow, SNV or small indel mutation in pre-treatment sample only; purple,
mutation in pre-treatment sample but post-treatment sample excluded;
lime green, mutation in post-treatment sample; blue, mutation present in
both pre- and post-treatment sample; clear, no mutation detected; orange,
more than one mutation present, with different directions of VAF change.
MSI, microsatellite instability.
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although mutations at low VAF in the pre-treatment lesion were
often lost from the post-treatment sample and a number of
mutations were unique to the latter, we reasoned that these
changes could be accounted for by sampling effects (Supple-
mentary Fig. 9). The two responders in this category (#10, #23)
both showed regression of the primary tumour by PET scan, as
well as histology.
A different pattern of evolution was seen in the two MSIþ
cancers, both non-responders. Mutations, including drivers, were
lost from the pre-treatment cancer across the VAF spectrum. In
fact, both MSIþ cancers contained three detectable, pathogenic
p53 mutations (p.Arg158His/p.Thr102fs/p.Pro72fs in #18 and
p.Arg267Trp/p.Pro191delCTC/p.Arg273Cys in #30) and the
sequencing of additional FFPE tumour regions showed that
some of these changes were spatially heterogeneous (Fig. 3). Each
cancer showed loss or severe VAF reduction of one of these
mutations in the post-treatment sample, while the other two
mutations increased in VAF. The post-treatment samples had
very large numbers of unique mutations across the VAF spectrum
and these included potential driver changes in PIK3R1 and
KMT2D. The genomic evolution of the MSIþ cancers strongly
suggested that these were polyclonal tumours. Another cancer
(#1) was MSI- and a responder, but also harboured three p53
mutations (p.Gly245Ser/p.Tyr220Cys/p.His193Pro), plus LOH,
and these mutations showed similar temporal and spatial
behaviour to those in the MSIþ cancers. We therefore included
this cancer in the polyclonal group although its level of clonal
complexity appeared lower than that of the MSIþ cases.
A further 10 cancers (Fig. 1) showed evidence of having passed
through a genetic bottleneck of varying severity based on the
following features (Fig. 4; Supplementary Fig. 8): loss of many
mutations, including some not at low VAFs, from the
pre-treatment sample; sharing of a non-trivial number of
mutations between pre- and post-treatment samples; and
increased frequency in the post-treatment samples of a clone
that was uncommon in the pre-treatment sample. Most, but not
all, cancers that had passed through a bottleneck were responders
(Fig. 1). In the two non-responders with evidence of a bottleneck
(#11, #12), there was evidence of some radiological reduction in
tumour volume after the course of chemotherapy. Some of the
‘bottlenecker’ cancers showing the clearest behaviour were as
follows. Cancer #6 was noteworthy for having lost its p53
mutation after treatment owing to loss of the clone containing
this mutation. The post-treatment cancer retained its pathogenic
CDKN2A and SMARCA4 mutations and gained a low VAF,
truncating ARID1A change. In cancer #8, p53, SMAD4,
CNTNAP5 and 1,006 other mutations were lost entirely after
treatment. Some of these changes, such as p53 and CNTNAP5
loss, could potentially be explained by SCNAs, although most
could not (details not shown). The post-treatment sample of #8
harboured 170 mutations with VAF40.03 (112 of which were
not found pre-treatment), 85 with VAF40.1 and 25 with
VAF40.2. In the absence of sequencing quality issues (for which
there was no evidence) or major non-neoplastic clone(s) present
in this sample (which is an intriguing possibility that remains
hypothetical), the loss of SMAD4—which is the only EAC driver
reported as mutated in carcinomas but not in precursors such as
Barrett’s oesophagus38—raises the possibility that the remaining
post-treatment cancer in patient #8 represents an earlier stage of
EAC development, such as an early cancer or even severe
dysplasia. Cancer #11 showed loss of the major pre-treatment
clone after treatment, and expansion of a sub-population of
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cells from the minor clone. It also showed loss of one p53
mutation (c.919þ 1G4T splice site) and expansion of
another (p.Arg273His) after therapy. Two NOTCH1 mutations
(p.Pro1381fs, p.Ala465Thr) were lost and two other driver
mutations (FBXW7 p.Arg465Cys, SEMA5A p.Glu832X) were
within a sub-clone that expanded greatly after treatment. Cancer
#12 showed loss of the major pre-treatment clone and expansion
of a minor clone including p53 and SMARCA4 mutations. Cancer
#27 lost the major pre-treatment clone that contained a MYO18B
mutation after therapy, but gained p53 and CNTNAP5 mutations
not present before therapy, alongside expansion of a minor
pre-treatment clone. We subsequently found the p53 mutation to
be present in the additional FFPE tumour region analysed and
hence, spatially heterogeneous (sub-clonal) in the primary cancer.
The other cancers with probable bottlenecks variably showed loss,
gain and retention of driver mutations.
Putative clonal histories with respect to bottlenecking and
response are shown in schematic fashion in Fig. 5. Overall, we
found that responders tended to show bottlenecks and non-
responders, no major clonal shifts (Fig. 1), with the distribution of
responder and non-responder cancers between the three clonal
behaviours being formally non-random (P¼ 0.013, Fisher’s exact
test). We surmised that the four cancers discordant for response
and bottlenecking could be explained as follows: in bottleneckers
with Mandard grade 4 or 5 cancer at resection (#11, #12), there
was rapid tumour re-growth after an initially good response;
and in non-bottleneckers with a Mandard grade r3 tumour
(#10, #23), clonally uniform loss of cancer cells related to factors
other than their genotype may have occurred.
Driver mutations in post-chemotherapy samples. We searched
for mutations that could confer chemotherapy resistance and/or
drive the growth of cancers that had passed through a bottleneck,
speciﬁcally SNVs and focal SCNAs found only in the post-
treatment sample. Twenty-four SNVs were found in known
cancer driver genes (Table 2), some of which were EAC drivers
(p53, FBXW7, SMARC4A, CNTNAP5) and/or pan-cancer drivers
(for example, SF3B1 and TAF1). Ten of the 24 mutations were
scored as probably functional. Four post-treatment cancers also
showed focal copy number gains of ERBB2, CCND2, TERT and
CCNE1 that were absent from the pre-treatment samples
(Table 3). A further cancer (#22) acquired a homozygous deletion
of the gastrointestinal cancer predisposition gene MUTYH and,
in accordance with defective base excision repair, showed an
B3-fold increase in the proportion of G:C4T:A SNVs in the
post-treatment sample (Supplementary Fig. 10).
Other changes in the EAC genome after therapy. We examined
the spectrum of SNVs, comparing mutations that had deﬁnitely
occurred before therapy (either speciﬁc to the pre-treatment
sample or shared) with those that were present only in the
post-treatment samples. En masse, there were highly signiﬁcant
differences between the mutation spectra before and after
chemotherapy (Po0.0001, w2 test, Supplementary Fig. 10). Most
notably, there was a decrease in C4T frequency and an increase
in C4A frequency after treatment, as also found in a study of
eight samples by Muruguase et al.34. These changes were reﬂected
in signiﬁcant (Po0.01, Fisher’s exact test) overall mutation
spectrum changes between individual pre- and post-treatment
pairs in 11/23 patients (Supplementary Fig. 10), in some cases
owing to large shifts in the frequencies of mutations other than
C4T and C4A. Several cancers showed a change in mutation
signature from S3 to S1 or S2 following treatment (Fig. 2;
Supplementary Fig. 5). Good responders were more likely to show
a signature change (P¼ 0.05, Fisher’s exact test), suggesting that
the signature resulted from the effects of chemotherapy, either
directly (for example, from nucleotide excision repair of platinum
adducts), or from the selection of a resistant sub-clone that had
few ageing-associated mutations, but had acquired mutations on
a speciﬁc environmental background.
Excluding the MSIþ cancers that had very low SCNA
burdens, the median proportion of large SCNAs shared
between the 21 pre- and post-treatment pairs analysed was
38% (range 6–95%; Supplementary Fig. 6). In keeping with the
SNV clonal shift data, fewer mutations were shared by the
pre- and post-treatment samples of responders than
of non-responders (medians 32% versus 47% shared,
P¼ 0.033, Wilcoxon test). A similar association was seen with
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bottlenecking, although this was formally non-signiﬁcant,
plausibly owing to the excluded samples (medians 34% versus
46%, P¼ 0.100). Gain of chromosome 4q and loss of 1q
and 20 were speciﬁcally more frequent in post-treatment than
pre-treatment cancers, especially those of responders (Supple-
mentary Fig. 6).
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Figure 5 | Schematic of putative evolution and sampling of patients with respect to genetic bottlenecks and clinical response. Although the effects of
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Table 2 | Cancer driver mutations speciﬁc to post-chemotherapy tumours of responders and/or bottleneckers.
Case Chr Position Gene Mutation Functional?
5 X 123,220,581 STAG2 p.Gly1080Arg/c.3238G4A Possible
6 2 198,267,720 SF3B1 p.Tyr587His/c.1759T4C Probable
6 12 56,482,338 ERBB3 p.Val296Met/c.886G4A Probable
7 3 126,722,305 PLXNA1 p.Glu504Lys/c.1510G4A Possible
7 4 144,446,615 SMARCA5 p.Gly178Ser/c.532G4A Probable
7 4 187,628,194 FAT1 p.Pro930Ala/c.2788C4G Unlikely
7 14 58,817,866 ARID4A p.Lys494_Asp495ins2/c.1482_1483ins6bp Probable
7 15 57,545,555 TCF12 p.Ile456fs/c.1366_1367ins13 Yes
7 21 35,154,412 ITSN1 p.Ile600Thr/c.1799T4C Probable
8 10 32,561,062 EPC1 p.Ala633Ser/c.1897G4T Possible
8 12 124,812,146 NCOR2 p.Glu2338fs/c.7012delG Probable
9 7 140,494,212 BRAF p.Phe346Leu/c.1036T4C Unlikely
11 2 198,269,813 SF3B1 p.Pro509Gln/c.1526C4A Probable
11 3 168,845,652 MECOM p.Gln270His/c.810A4C Probable
11 9 16,419,233 BNC2 p.Glu1018Asp/c.3054A4T Unlikely
11 X 70,598,761 TAF1 p.Asp413His/c.1237G4C Probable
12 20 31,022,659 ASXL1 p.Arg710Lys/c.2129G4A Unlikely
22 12 49,437,523 KMT2D p.Ala1788Thr/c.5362G4A Possible
27 2 74,128,460 ACTG2 p.Ala8Thr/c.22G4A Probable
27 2 125,555,816 CNTNAP5 p.Val1045Leu/c.3133G4T Unlikely
27 6 129,766,853 LAMA2 p.Ala2106Pro/c.6316G4C Possible
27 6 152,647,435 SYNE1 p.Gln5097X/c.15289C4T Possible
27 17 7,578,190 TP53 p.Tyr220Cys/c.659A4G Yes
28 11 3,707,397 NUP98 p.Glu1494Asp/c.4482G4T Possible
Driver mutation status was obtained from the IntOGen database. The predicted functionality is shown as Yes (proven)/probable/possible/unlikely as assessed using functional prediction
(SIFT, Polyphen2) and previous reports of mutations at that residue in COSMIC and the cBIO portal.
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Sequencing of additional tumour regions. For four cancers
(#16, #18, #27 and #28), extra regions of both pre- and post-
treatment cancer were available from FFPE tissue, and additional
single pre- or post-treatment FFPE samples were available from a
further nine cancers. These samples were sequenced using
the Ampliseq Comprehensive Cancer Panel. Median average
sequencing depth (Supplementary Fig. 11) was 1,228 (range
463–2,373). A few samples harboured driver gene mutations
(in ARID1A and NOTCH1) that had not been not found by
exome sequencing or Ampliseq in the equivalent FF sample and
conversely, some frozen sample driver mutations, notably also in
NOTCH1, were absent from the FFPE samples (Supplementary
Table 8). In the whole set of FFPE samples, excluding NOTCH1
mutations that appear often to be polyclonal34, 55/66 (83.3%)
mutations were concordantly present or absent in the FF and
FFPE samples. A small number (N¼ 7) of mutations apparently
gained in the post-treatment FF sample were actually present in
the FFPE pre-treatment sample, indicating spatial sub-clonal
heterogeneity in the latter and artefactual gain owing to
sampling effects34. Genetic divergence between spatially distinct
pre-treatment biopsies was not predictive of response to therapy
(details not shown).
Discussion
The clinicopathological response of oesophageal adenocarcinoma
to neo-adjuvant chemotherapy predicts survival after surgery1,
whether as a direct consequence of residual tumour burden, or as
a marker of how effectively metastases have been treated. In this
study, we have shown that the response of the EAC genome to
neo-adjuvant oxaliplatin and 5-ﬂuorouracil varies greatly, with
cancers falling into three main groups. First, some EACs appear
intrinsically resistant to therapy and show only minor genomic
changes after treatment, plausibly resulting from tumour
sampling effects alone. Second, a small number of cancers,
especially MSIþ lesions, tend to have multiple driver gene
mutations that variably increase or decrease in frequency after
treatment, sometimes showing complete loss or gain. However,
the overall genetic complexity of the cancer is largely unchanged
by therapy. We propose that these tumours have a high degree of
polyclonality and spatial heterogeneity, such that the observed
changes after treatment largely reﬂect sampling effects, although
differential effects of therapy on sub-clones remain possible. In
the ﬁnal group of cancers, profound clonal shifts strongly
reminiscent of genetic bottlenecking occur. A good clinical
response is associated with a bottleneck, but importantly,
some poor responders go through bottlenecks and some good
responders do not.
We used p53 as an exemplar for the behaviour of EAC driver
mutations after chemotherapy. While we took considerable care
to address the inﬂuence of treatment-induced changes in tumour
purity on our major ﬁndings and excluded six cancers on that
basis, we accept that some instances of p53 loss in the remaining
24 cancers might still be artefacts of low purity in post-treatment
samples. In other cases, p53 loss might simply result from a
SCNA deleting the mutant allele, leaving a tumour that remains
p53-deﬁcient, although the replacement of a missense mutation
with a null mutation might still have functional consequences49.
Irrespective of potential purity problems, however, we believe that
the three types of clonal evolution described above remain valid.
While some cancers retain their p53 mutation after treatment,
others harbour multiple p53 SNVs and/or SCNAs that can be
lost, gained or change in frequency after treatment, even if the
post-treatment cancer remains p53-mutant. These data strongly
suggest that p53 mutations can be polyclonal in EACs. Finally, as
seen most clearly in cancer #6, p53 mutations can be lost in the
absence of a copy number change as it resides within an EAC
sub-clone that is lost as the cancer passes through a genetic
bottleneck. We speculate that the few complete pathological
responders in the clinical trial (who could not, of course, be
analysed) may have shown even more severe bottlenecking than
that found in our analysable, good responder cancers.
The nature of the remaining tumour in good responders is a
little uncertain, as EAC morphology after chemotherapy can be
hard to assess. It has been speculated that precursor lesions such
as Barrett’s oesophagus are more resistant to chemotherapy than
EAC proper. We wonder whether early EAC or severely
dysplastic Barrett’s oesophagus was present at non-trivial levels
in some of our post-treatment specimens, for example reﬂecting
the loss of the SMAD4 mutation after treatment in cancer #8.
Since Barrett’s oesophagus may be polyclonal and variably
harbours p53 and other driver mutations, this scenario might
also explain the loss of p53 mutation in cancer #6. Further work
is, however, required to conﬁrm or refute this possibility.
Studies of haematological malignancies have shown that
genetic bottlenecks can occur in patients who relapse after
an initially good response. In a few cases, they have also
demonstrated large changes in known driver genes. For example,
Grifﬁth et al.50 showed loss of IDH1 mutation, accompanied by an
IDH2 mutation rising from 2% frequency to clonal driver status in
an acute myelogenous leukaemia (AML) patient, similar to our
ﬁndings for p53 in cancer #11. Fewer studies have examined the
effects of chemotherapy on the carcinoma genome, especially in
the neo-adjuvant setting in which response, rather than recurrence,
is the primary endpoint. Our results are, however, consistent with
previous reports. Using targeted Sanger sequencing and
Pyrosequencing, Jiang et al.28 reported that the allele frequencies
of p53 and PIK3CA mutations tended to fall in breast cancers after
they responded to taxol and carboplatin, but the study did not
perform deep sequencing or examine tumour purity changes.
Other groups have reported that recurrent brain tumours can show
bottleneck behaviour affecting the major clone after genotoxic
primary or adjuvant treatment with temozolomide32,33. Of note,
the brain tumour studies found no good evidence of speciﬁc,
recurrent chemotherapy resistance mutations. Possible
explanations for this include polygenic mechanisms of resistance,
multiple resistant sub-clones within cancers, chemoresistance of
non-genetic origins and large-scale genetic heterogeneity resulting
in many potential resistance genes, and hence sub-optimal power
for their detection. In general, our data were in accordance with the
brain tumour ﬁndings, although we did ﬁnd a few cancer-
associated mutations that could have conferred therapeutic
resistance and/or acted as post-chemotherapy drivers.
As regards EAC sequencing, a recent study by Murugaesu
et al.34 examined neo-adjuvant chemotherapy in eight EAC
patients, with a focus on multi-region sequencing. Our study is
concordant with Murugaesu et al. in some respects, including the
importance of SCNAs, sub-clonal NOTCH1 mutations, the
Table 3 | Focal copy number driver mutations speciﬁc to
post-chemotherapy tumours of responders and/or
bottleneckers.
Case Chr Start position End position Gene Gain/deletion
4 17 37,771,746 38,948,438 ERBB2 Gain
10 12 4,066,795 4,823,986 CCND2 Gain
22 1 44,844,958 46,743,900 MUTYH Deletion
27 5 38,139 1,493,608 TERT Gain
27 19 28,959,499 30,105,969 CCNE1 Gain
These changes were present only in the post-treatment samples of the 23 cancers analysed for
SCNAs.
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widespread genome doubling, and the change in mutation
spectrum after chemotherapy. However, Murugaesu et al. did
not perform very deep sequencing or array-based SCNA
assessment, and examined only one responder who had post-
treatment samples available. They were consequently unable
systematically to examine genetic bottlenecks or relate the
genomic changes they found to patient response. Murugaesu
et al. reported that EACs have stable genetic vulnerabilities,
unimpeded by cytotoxics and suitable for therapeutic inter-
vention, but our data show that this is not generally true,
although it holds for a sub-set of patients, largely poor
responders.
It is interesting that platinum therapies are postulated to
require deﬁcient homologous recombination for their effects.
Several studies (summarized in ref. 51), have suggested p53
mutations to be a marker of poor response and outcome in EAC.
p53 mutation has also been suggested as causal for platinum
resistance owing to the failure of pro-apoptotic pathways.
Typically, however, associations between tumour markers
and pathological response to chemotherapy are assessed using
surgical resection specimens. In our study, p53 mutations were
indeed over-represented in the post-treatment samples of
non-responders (P¼ 0.046, Fisher’s exact test). However, it was
not the p53 SNV in the primary cancer, but persistence of
p53 mutation in the post-treatment tumour that was associated
with a poor outcome. It follows that biomarkers derived from
post-therapy samples should be used with caution in the clinical
setting.
Our study has some clinical implications. For example,
molecular (bottleneck) and clinical (enhanced PET) response
are not always in accordance. This is of particular clinical
importance, as presently a number of centres and studies
use interval metabolic response on PET after one cycle of
chemotherapy as a surrogate of response, and a basis for aborting
or continuing neo-adjuvant therapy52. Similar considerations
apply to Mandard grade, which remains the mainstay of assessing
response after surgery, but is prone to inter-observer variability.
Not only can a clinical response occur without a bottleneck, but
more importantly a bottleneck can occur in the absence of an
apparent clinical response. In the latter case, it is quite possible
that the cancer has responded well initially and re-grown equally
rapidly, either subsequent to shrinkage of the major clone or in
parallel with it. This begs the question of whether additional
therapy, in parallel or contiguously, could prevent emergence of
the resistant clone in bottlenecker non-responders.
In summary, even a short course of pre-operative chemo-
therapy can cause rapid EAC genome evolution. Similarly rapid
changes have been shown when tumours acquire resistance to
targeted therapies24. A good clinical response and/or genetic
bottlenecking is predicted by a large SNV burden and high
proportion of T:A4A:T mutations in the pre-treatment EAC
although not by the level of genetic diversity. The clinical utility of
these biomarkers requires assessment in independent studies.
A good response is usually accompanied by a variably tight
genetic bottleneck, although bottlenecks also occur in some non-
responders. The remaining cells in such tumours may harbour
driver mutations not detectably present in the primary cancer. By
contrast, many other EACs, especially non-responders, show
relatively few new genetic changes after therapy. Overall, our data
suggest that anti-EAC therapy should not be based solely on
pre-treatment biopsies. Instead, a combination of improved
imaging52 and molecular monitoring during treatment—for
example, by repeated biopsies or using circulating tumour
DNA—has the potential to classify response better and to
suggest timely additional treatment strategies based on cytotoxics
or therapies targeted to mutations in the residual cancer.
Methods
Patients and samples. Patients with oesophageal adenocarcinoma were drawn
from a phase II of neo-adjuvant oxaliplatin and 5-ﬂuorouracil for oesophageal
cancer (EudraCT number 2005-000834-34). All patients provided written informed
consent for treatment and molecular analysis, with ethical approval provided by the
Oxfordshire Regional Ethics Committee. Recruitment took place between May
2006 and February 2010. Inclusion criteria were: age over 18 years; histological
evidence of locally advanced (4T1N0; UICC-AJCC 6th edition 37) invasive cancer
of the oesophagus or gastro-oesophageal junction (excluding Siewert type III
tumours); no evidence of unresectable disease; World Health Organisation (WHO)
performance status 0–2; absence of any clinically signiﬁcant disease likely to
interfere with study evaluations; and adequate haematological, renal and hepatic
function. Exclusion criteria included: pregnant or breast-feeding women; and
dihydropyrimidine dehydrogenase deﬁciency. Patients were staged sequentially by
contrast-enhanced CT, endoscopic ultrasound (EUS), 18F-FDG PET-CT, and
laparoscopy (for tumours extending below the diaphragm). Patients received
two cycles of oxaliplatin-5FU: each lasted 21 days, and comprised 130mgm 2
intravenous oxaliplatin on day 1, followed by 1,000mgm 2 per day intravenous
5-ﬂuorouracil on days 1–4. Following completion of therapy, restaging was
performed by PET-CT. In the absence of progression to unresectable disease,
patients underwent attempted surgical resection 4–6 weeks later.
Forty of 51 patients in the trial had adenocarcinoma. Random biopsies
comprising 2–3mm3 of the primary cancer and normal squamous oesophageal
epithelium 5–10 cm proximally were taken at endoscopic ultrasound examination
within 3 weeks of diagnosis and before instigation of therapy. Some of these
samples were snap-frozen; others were ﬁxed in formalin and parafﬁn embedded.
Serial haematoxylin-and-eosin examination conﬁrmed the presence of an
estimated 460% malignant cells in each cancer sample. Thirty-six patients
proceeded to surgery 12–14 weeks after diagnosis (one patient died during
chemotherapy, one was unable to undergo resection due to performance status, and
two had metastatic disease evident on re-staging scan). In 2 of the 36, unresectable
disease was encountered; successful resection was therefore performed in 34
patients. Of these, the resection specimen underwent histopathological assessment
within 1 h of resection, and 3–4mm3 macrodissected samples were taken randomly
from areas of cancer and frozen for molecular analysis; haematoxylin-and-eosin
examination conﬁrmed the presence of an estimated470% malignant cells in each
sample. One tumour underwent complete histopathological regression, leaving 33
tumours potentially suitable for analysis, of which 30 were chosen. Normal tissue
45 cm proximal to the primary tumour was again taken and frozen for analysis.
Mandard grading was performed before molecular work being performed
according to the standard criteria by two independent, blinded observers
(J.M.F. and L.M.W.) with any discordance resolved by consensus.
Genomic DNA was extracted from tumour and normal samples after
homogenization using the Qiagen Dneasy Blood and tissue kit according to the
manufacturer’s instructions. Total messenger RNA was also extracted using the
Qiagen AllPrep DNA/RNA Micro Kit (Qiagen Inc., Valencia, CA) in accordance
with the manufacturer’s instructions.
Exome sequencing. Exome capture was performed using the Illumina TruSeq or
Nextera method. Samples were quantiﬁed using the Qubit system (Invitrogen) and
sequencing libraries constructed from 1 mg DNA post capture using the NEBNext
DNA Sample Prep Master Mix Set 1 Kit (NEB). Ligation of adaptors was
performed using 6 ml of the Illumina Multiplexing Sample Preparation
Oliogonucleotide Kit. Libraries were size-selected using 2% gel electrophoresis and
the distribution of fragments in the puriﬁed fraction was determined using the
Tapestation 1DK system (Agilent/Lab901). Each library was PCR-enriched using
the following custom primers:
Multiplex PCR primer 1.0:
50-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG
CTCTTCCGATCT-30
Index primer:
50-CAAGCAGAAGACGGCATACGAGAT[INDEX]CAGTGACTGGAGTTC
AGACGTGTGCTCTTCCGATCT-30
Indexes were 8 bp long and part of a system developed in-house. Four
independent PCR reactions per sample were prepared using 25% volume of the
pre-PCR library each. After eight cycles of PCR (cycling conditions as per Illumina
recommendations), the four reactions were pooled and puriﬁed with AmpureXp
beads. The ﬁnal size distribution was determined using the Tapestation 1DK
system (Agilent/Lab901). The concentration of each library was determined by the
Agilent qPCR Library Quantiﬁcation kit. Samples were sequenced using the
Illumina HiSeq2000 platform as paired 100 bp reads with Chemistry version 3.0,
with the aim of a target average coverage of 100 for the blood DNA and 200
for the tumours.
Reads were mapped with Stampy version 1.0.21 (ref. 53) and BWA version 0.7.0
(ref. 54) onto the decoy Human Reference Genome (GRCh37d5). Duplicated reads
were removed with Picard suite (version 1.111) (http://broadinstitute.github.io/
picard/) and realigned around indels with the Genome Analysis Toolkit version
3.1-1 (ref. 55). SNVs and small insertion–deletions (indels) were called with
Platypus version 0.5.2 (ref. 56). Normal, pre-chemotherapy tumour (BT) and post-
chemotherapy tumour (AT) samples were analysed together to ensure comparable
calls at every locus. Reads with mapping quality o30 and base quality o20 were
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discarded. Variants were only kept if they passed the standard Platypus ﬁltering
criteria, with the exception of variants showing allele bias to increase sensitivity for
mutations in sub-clones or SCNAs. An additional set of SNVs was identiﬁed using
MuTect version 1.1.4 (ref. 57) to increase our sensitivity for somatic mutations.
Variants were annotated using SnpEff version 3.6b (ref. 58) and VCFtools version
0.1.12 (ref. 59).
Putative somatic mutations were deﬁned as variant sites in any of the tumours
that were different from the paired normal samples. Then, an empirically based
ﬁltering was applied to identify high reliable/quality somatic variants, speciﬁcally
removing:
(i) less than 10 reads in total at the variant site in the normal sample and o8
reads in tumour samples;
(ii) VAF Z0.03 in normal;
(iii) less than four variant alleles;
(iv) VAF r0.02;
(v) presence of variant in public databases of germline variants (Exome Variant
Server, 1000 genomes project, Complete Genomics 69 reference genomes) at
a frequency Z1%;
(vi) variants identiﬁed in constitutional DNA from any of the other local,
non-cancer sequencing projects (for example, 29 million variants across 284
samples from the Oxford-Illumina WGS500 consortium), owing to their
likely origin as systematic errors in our pipeline; and
(vii) presence in a segmental duplication region (490% homology) or a region
with mappability score o0.8.
Since we wished to compare pre- and post-treatment samples, we required only
one member of each tumour pair to pass ﬁlters (iii) and (iv). Finally, for selected
variants, and all variants in EAC driver genes (whether detected using exome
sequencing or Ampliseq), we made sure the automatic call matched the data by
expert visual inspection (I.T.) of the reads mapped onto the reference genome
using read direction colouring on top of the standard integrated genomics viewer
scheme (http://www.broadinstitute.org/igv/alignmentdata/). All variants in regions
of poor quality were excluded.
Ion proton sequencing. The Lifetech/ThermoFisher Ion AmpliSeq comprehensive
cancer panel (http://www.lifetechnologies.com/order/catalog/product/4477685)
was used for technical validation and deep sequencing of exome sequence data
using the same FF DNA samples as used previously, and additionally for a small
number of sample trios and some unpaired samples with additional formalin-ﬁxed,
parafﬁn-embedded biopsies from the same patients. A total of 40–60 ng of total
genomic DNA was used to amplify targets according to the manufacturer’s
protocol (LifeTechnologies, cat. no. 4477685 and 4480442). Brieﬂy, PCR cycling
used for amplifying target DNA was an initial denaturation step at 99 C for 2min,
followed by 16 cycles of 99 C for 15 s and 60 C for 8min. The primer sequences
within the PCR products were partially digested with FuPa reagent at 50 C for
10min, 55 C for 10min and 60 C for 20min, followed by ligation of IonXpress
sequencing barcode adaptors (cat. no. 4471250). Adaptor-ligated DNA was puriﬁed
using Agencourt AMPure XP reagent beads (Beckman Coulter, cat. no. A63881).
Library ampliﬁcation was performed with an initial denaturation at 98 C for
2min, followed by ﬁve cycles of 98 C for 15 s and 60 C for 1min. Libraries were
size-selected between 100 and 300 bp using Agencourt AMPure XP reagent beads
and eluted in 50ml lowTE (Life Technologies). Libraries were quantiﬁed using the
Agilent Bioanalyzer high sensitivity DNA kit (Agilent, cat. no. 5067–4626).
A volume of 70ml of diluted libraries at 200 pM were loaded via the Ion Chef
instrument (Life Technologies, cat. no. 4484177) onto Ion PI chip v2 BC (cat. no.
4484270). Chips were sequenced on the Ion Proton sequencer (cat. no. 4476610)
initialized with the Ion PI CI sequencing 200 kit (cat. no. 4488377) according to the
manufacturer’s instruction. Signal processing and base calling were performed
using the Ion Proton Torrent suite (version 4.4). Variant calling was performed
using variantCaller and Ion Reporter with a generic default parameter. The sites of
variants present in the Ampliseq and/or exome sequence data were assessed
alongside each other using both automatic calls in the Torrent Server output and
visual inspection in the integrated genomics viewer.
The quality control ﬁlters were set as per the exome sequencing data,
except that tumour minimum VAF was set at 0.02 for the FF samples (to reﬂect
standard Ion Reporter somatic calling for high-depth sequencing) and 0.05 for the
formalin-ﬁxed, parafﬁn-embedded samples to reﬂect greater potential PCR bias
and possible low-level deamination. Again, all variants passing VAF thresholds in
one sample were visually inspected and reported in the other samples.
Mutational signatures. Signatures of somatic mutations were inferred using
the Bioconductor SomaticSignature package version 2.2.1 (doi: http://dx.doi.org/
10.1101/010686). Brieﬂy, the observed mutation spectrum is mathematically
decomposed using a non-negative matrix factorization method60. The
decomposition was performer for an a priori set of two to eight signatures. The
optimal number of signatures (r¼ 3) was manually chosen based on the maximum
differentiation between the signatures. The conclusions of our analysis in terms of
spectral changes after therapy remained if two or four signatures were assumed.
Clonal structure analysis. Allelic heterogeneity, and thus clonal structure, was
evaluated using PyClone algorithm (version 0.12.3)61. Allelic frequencies of
selected somatic mutations were obtained using the number of reads and the
number of reads carrying a variant. The copy number value at each of these
loci was obtained from Onco-SNP (or VarScan2 where SNP array data were
unavailable). For multi-sample analysis, only somatic mutations shared between
pre-treatment and post-treatment samples, with at least 60 coverage in one of
the samples were included to provide a robust measure of clonal shifts based on
precedent33. In addition, we included also shared positions with an allelic ratio
o0.03 in just one of the samples. Mutations annotated as a candidate drivers were
included in all the analyses regardless of their coverage. PyClone was run with a
10,000 iterations and a burn-in of 1,000 as suggested by the authors (http://
compbio.bccrc.ca/software/pyclone/). To reduce the running time in the analysis of
hypermutated cancers #18 and #30, PyClone was run for these samples with a
randomly selected set of 500 variants.
Mutation and gene set analysis. Gene-based and pathway analyses to detect
signiﬁcantly over-represented mutant genes and pathways were performed
by IntOGen version 2.4.1 (ref. 40) and MutSigCV41 using the annotated,
quality-ﬁltered, somatic mutations. Mutation set analyses were performed using the
CPDB (http://cpdb.molgen.mpg.de/).
Copy number analysis. Where DNA was available, we analysed pre- and
post-treatment tumour samples using Illumina Core Exome 24 arrays using
standard methods. The OncoSNP v2.1 program (https://sites.google.com/site/
oncosnp/user-guide) was used in unpaired mode. We used the default top ranked
ploidy estimate. A copy number change was called if a region showed an absolute
copy number that differed from the genome-wide mean by41 in either direction.
LOH was called using the default program settings. We presented data from two
types of OncoSNP analysis: rank 1 (highest conﬁdence) calls, which tend to be large
regions of change; and all rank 1–5 calls, which include smaller regions with
somewhat weaker evidence in favour of SCNAs and/or LOH.
Where DNA was unavailable for SNP array analysis, copy number was
estimated using VarScan2 (version 2.3.7)62 using matched tumour-normal pairs
using default parameters and adjusting for data and GC content. Sex chromosomes
and low mappability regions extracted from the ENCODE ‘DAC blacklisted’ table
of the UCSC genome browser were excluded from the analysis. Winsorization
using the Median Absolute Deviation was performed to detect and modify extreme
logR values and genomic segments of constant logR were identiﬁed and merged at
individual level by the bioconductor package copynumber (version 1.6.0)63
(g¼ 1,000). Gains and losses were called using a logR threshold of ±0.15.
These data were only used for incorporation into the Pyclone program.
Microsatellite instability. MSI was evaluated in the exome sequence data with
MSIsensor version 0.2 (ref. 64) using default parameters and ﬁltered using a 0.05
false discovery rate threshold.
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